Medpace upgraded by TD Cowen with a new price target
$MEDP
Biotechnology: Commercial Physical & Biological Resarch
Health Care
TD Cowen upgraded Medpace from Sell to Hold and set a new price target of $419.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2026 | $547.00 | Outperform → Neutral | Robert W. Baird |
| 7/7/2026 | $515.00 | Buy → Hold | Jefferies |
| 3/6/2026 | $500.00 | Underweight → Equal Weight | Barclays |
| 3/3/2026 | $522.00 | Outperform | RBC Capital Mkts |
| 2/18/2026 | $419.00 | Sell → Hold | TD Cowen |
| 2/13/2026 | $560.00 | Hold → Buy | Jefferies |
| 2/10/2026 | $564.00 | Neutral → Outperform | Robert W. Baird |
| 11/13/2025 | $600.00 | Market Perform | BMO Capital Markets |
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%. Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x. Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period. Net income margin was 17.2% and 15.0% for the second quarter
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon
Robert W. Baird downgraded Medpace from Outperform to Neutral and set a new price target of $547.00
Jefferies downgraded Medpace from Buy to Hold and set a new price target of $515.00
Barclays upgraded Medpace from Underweight to Equal Weight and set a new price target of $500.00
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
Revenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%. Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x. Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period. Net income margin was 17.2% and 15.0% for the second quarter
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of